⏰ Last chance! Join Premium for $20/month before it increases to $49/month.

Inhibikase Therapeutics, Inc. Common Stock

$1.67
+0.00 (+0.00%)

Market Capitalization:

$233.02M

Live Price

Live Volume

Chart Volume 0
Volume 0
5 sec

Inhibikase Therapeutics Market Segments

Overnight

*No Trades in Segment

After Hours

*No Trades in Segment

Regular Trading Hours

*No Trades in Segment

Premarket

*No Trades in Segment

After Hours Yesterday

+0.00(+0.00%)
Open$1.67
Close$1.67
Low$1.67
Low Change0.00 (0.00%)
High$1.67
High Change+0.00 (+0.00%)
Range$0.00
Volume90.752K
Dollar Volume$151.56K

Regular Trading Hours Yesterday

+0.03(+1.83%)
Open$1.64
Close$1.67
Low$1.63
Low Change-0.02 (-0.91%)
High$1.70
High Change+0.06 (+3.35%)
Range$0.07
Volume756.933K
Dollar Volume$1.26M

Premarket Yesterday

*No Trades in Segment

Inhibikase Therapeutics News

There is no current news for this stock at the moment.

Inhibikase Therapeutics Top Trades

We are still processing the top long and short trades for today. Please refresh the page in 10 minutes or sign up for Finsuba Premium for real time trade insights.

Inhibikase Therapeutics Moving Averages

5 Day Moving Average (SMA5)$1.59
10 Day Moving Average (SMA10)$1.63
20 Day Moving Average (SMA20)$1.77
50 Day Moving Average (SMA50)$2.09
100 Day Moving Average (SMA100)$2.10
200 Day Moving Average (SMA200)$1.94

Inhibikase Therapeutics Statistics

Average Volume (30 Days)525.93K
P/E Ratio (Current)-4.58
EPS (Current)-$0.43
Dividend Yield0.00%
Free Cash Flow-$42.61M
Cash Ratio3.04
Current Ratio15.82
Quick Ratio15.82
Debt to Equity0.00
Enterprise Value$243.68M
EV to EBITDA-3.73
EV to Sales—
Price to Book1.79
Price to Cash Flow—
Price to Free Cash Flow—
Price to Sales—
Return on Assets-0.37%
Return on Equity-0.40%

Inhibikase Therapeutics Stock Splits

There has been 1 stock split for Inhibikase Therapeutics (IKT). The reverse stock split occured on June 30, 2023 and reduced the outstanding shares at a ratio of 6:1.

DateTypeRatio
Jun 30, 2023Reverse6:1

Inhibikase Therapeutics Dividends

There have been no dividends for Inhibikase Therapeutics (IKT).